<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "8: Forwardlooking ", fill: "#f8f8ff"},
{source: "8: Forwardlooking ", target: "8: statements may", fill: "#f8f8ff"},
{source: "8: statements may", target: "8: such matters as", fill: "#f8f8ff"},
{source: "8: such matters as", target: "8: generate future revenues", fill: "#f8f8ff"},
{source: "8: generate future revenues", target: "8: commercialization", fill: "#f8f8ff"},
{source: "8: commercialization", target: "8: ongoing operation", fill: "#f8f8ff"},
{source: "8: ongoing operation", target: "8: facilities", fill: "#f8f8ff"},
{source: "8: facilities", target: "8: adequate amounts", fill: "#f8f8ff"},
{source: "8: adequate amounts", target: "8: products ourselves", fill: "#f8f8ff"},
{source: "8: products ourselves", target: "8: through thirdparty manufacturers", fill: "#f8f8ff"},
{source: "8: through thirdparty manufacturers", target: "8: optimization", fill: "#f8f8ff"},
{source: "8: optimization", target: "8: production costs", fill: "#f8f8ff"},
{source: "8: production costs", target: "8: enter into future", fill: "#f8f8ff"},
{source: "8: enter into future", target: "8: collaborations", fill: "#f8f8ff"},
{source: "8: collaborations", target: "8: partnerships", fill: "#f8f8ff"},
{source: "8: Forwardlooking ", target: "13: nutritional oil products sales", fill: "#6da"},
{source: "13: nutritional oil products sales", target: "13: customers under agreements with no minimum purchase", fill: "#6da"},
{source: "13: customers under agreements with no minimum purchase", target: "13: requirements", fill: "#6da"},
{source: "13: nutritional oil products sales", target: "15: product sales", fill: "#979aaa"},
{source: "15: product sales", target: "15: existing customers", fill: "#979aaa"},
{source: "15: product sales", target: "16: Approximately ", fill: "#000080"},
{source: "16: Approximately ", target: "16: product sales revenue during", fill: "#000080"},
{source: "16: product sales revenue during", target: "16: generated by sales", fill: "#000080"},
{source: "16: generated by sales", target: "16: DHA and ARA ", fill: "#000080"},
{source: "16: Approximately ", target: "17: cannot guarantee", fill: "#ff8c69"},
{source: "17: cannot guarantee", target: "17: customers will continue", fill: "#ff8c69"},
{source: "17: customers will continue", target: "17: nutritional products at current", fill: "#ff8c69"},
{source: "17: nutritional products at current", target: "17: predictable levels", fill: "#ff8c69"},
{source: "17: cannot guarantee", target: "18: agreements", fill: "#aa98a9"},
{source: "18: agreements", target: "18: license agreements allow", fill: "#aa98a9"},
{source: "18: license agreements allow", target: "18: manufacture", fill: "#aa98a9"},
{source: "18: manufacture", target: "18: products themselves", fill: "#aa98a9"},
{source: "18: products themselves", target: "18: purchase nutritional", fill: "#aa98a9"},
{source: "18: agreements", target: "22: success depends upon", fill: "#ffe4e1"},
{source: "22: success depends upon", target: "22: competitive", fill: "#ffe4e1"},
{source: "22: competitive", target: "22: infant formula", fill: "#ffe4e1"},
{source: "22: infant formula", target: "22: adult nutritional product markets", fill: "#ffe4e1"},
{source: "22: success depends upon", target: "52: OmegaTech Inc", fill: "#966fd6"},
{source: "52: OmegaTech Inc", target: "54: OmegaTech ", fill: "#ec3b83"},
{source: "54: OmegaTech ", target: "54: fermentable", fill: "#ec3b83"},
{source: "54: fermentable", target: "54: accumulated", fill: "#ec3b83"},
{source: "54: accumulated", target: "54: pending patents protecting", fill: "#ec3b83"},
{source: "54: pending patents protecting", target: "54: technology", fill: "#ec3b83"},
{source: "54: OmegaTech ", target: "62: liabilities", fill: "#008000"},
{source: "62: liabilities", target: "62: FermPro Manufacturing LP ", fill: "#008000"},
{source: "62: FermPro Manufacturing LP ", target: "62: fermentation", fill: "#008000"},
{source: "62: fermentation", target: "62: facility located", fill: "#008000"},
{source: "62: facility located", target: "62: Kingstree South Carolina", fill: "#008000"},
{source: "62: liabilities", target: "65: Martek DHA ", fill: "#f6adc6"},
{source: "65: Martek DHA ", target: "65: Martek DHA", fill: "#f6adc6"},
{source: "65: Martek DHA", target: "65: Mead Johnson ", fill: "#f6adc6"},
{source: "65: Mead Johnson ", target: "65: nursing women containing", fill: "#f6adc6"},
{source: "65: Martek DHA ", target: "START_HERE", fill: "#f6adc6"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dietary_supplement">Dietary supplement</a></td>
      <td>A dietary supplement is a manufactured product intended to supplement one's diet by taking a pill, capsule, tablet, powder, or liquid. A supplement can provide nutrients either extracted from food sources or that are synthetic in order to increase the quantity of their consumption.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fish_oil">Fish oil</a></td>
      <td>Fish oil is oil derived from the tissues of oily fish. Fish oils contain the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), precursors of certain eicosanoids that are known to reduce inflammation in the body and improve hypertriglyceridemia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sales">Sales</a></td>
      <td>Wales (Welsh: Cymru [ˈkəm.rɨ] (listen)) is a country that is part of the United Kingdom. It is bordered by England to the east, the Severn Estuary to the south-east, the Bristol Channel to the south, the Celtic sea to the south-west and the Irish Sea to the west and north.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sales_promotion">Sales promotion</a></td>
      <td>Sales promotion is one of the elements of the promotional mix. The primary elements in the promotional mix are advertising, personal selling, direct marketing and publicity/public relations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_life-cycle_management_(marketing)">Product life-cycle management (marketing)</a></td>
      <td>Product life-cycle management (PLM) is the succession of strategies by business management as a product goes through its life-cycle. The conditions in which a product is sold (advertising, saturation) changes over time and must be managed as it moves through its succession of stages.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/End-of-life_product">End-of-life product</a></td>
      <td>An end-of-life product (EOL product) is a product at the end of the product lifecycle which prevents users from receiving updates, indicating that the product is at the end of its useful life (from the vendor's point of view). At this stage, a vendor stops the marketing, selling, or provision of parts, services or software updates for the product.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sales_presentation">Sales presentation</a></td>
      <td>In selling technique, a sales presentation or sales pitch is a line of talk that attempts to persuade someone or something, with a planned sales presentation strategy of a product or service designed to initiate and close a sale of the product or service.\nA sales pitch  is essentially designed to be either an introduction of a product or service to an audience who knows nothing about it, or a descriptive expansion of a product or service that an audience has already expressed interest in.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Docosahexaenoic_acid">Docosahexaenoic acid</a></td>
      <td>Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina.  In physiological literature, it is given the name 22:6(n-3).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Beech-Nut">Beech-Nut</a></td>
      <td>Beech-Nut Nutrition Corporation is a baby food company owned by the Swiss branded consumer-goods firm Hero Group.\n\n\n== History ==\n\nBeech-Nut's roots go back to 1891, to the Mohawk Valley town of Canajoharie, New York.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gynoid_fat_distribution">Gynoid fat distribution</a></td>
      <td>Gynoid fat is the body fat that forms around the hips, breasts and thighs. Gynoid fat in females is used to provide nourishment for offspring, and is often referred to as 'reproductive fat'.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/NASA_spinoff_technologies">NASA spinoff technologies</a></td>
      <td>NASA spinoff technologies are commercial products and services which have been developed with the help of NASA, through research and development contracts, such as Small Business Innovation Research (SBIR) or STTR awards, licensing of NASA patents, use of NASA facilities, technical assistance from NASA personnel, or data from NASA research. Information on new NASA technology that may be useful to industry is available in periodical and website form in "NASA Tech Briefs", while successful examples of commercialization are reported annually in the NASA publication "Spinoffs".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arachidonic_acid">Arachidonic acid</a></td>
      <td>Arachidonic acid (AA, sometimes ARA) is a polyunsaturated omega-6 fatty acid 20:4(ω-6), or 20:4(5,8,11,14).  It is structurally related to the saturated arachidic acid found in cupuaçu butter.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bashkir_language">Bashkir language</a></td>
      <td>Bashkir (; Bashkir: Башҡортса Bashqortsa, Башҡорт теле Bashqort tele, [bɑʃˈqort tɘˈlɘ] (listen)) is a Turkic language belonging to the Kipchak branch. It is co-official with Russian in Bashkortostan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Infant_formula">Infant formula</a></td>
      <td>Infant formula, baby formula or just formula (American English) or baby milk, infant milk, false milk, or first milk (British English), is a manufactured food designed and marketed for feeding to babies and infants under 12 months of age, usually prepared for bottle-feeding or cup-feeding from powder (mixed with water) or liquid (with or without additional water). The U.S. Federal Food, Drug, and Cosmetic Act (FFDCA) defines infant formula as "a food which purports to be or is represented for special dietary use solely as a food for infants by reason of its simulation of human milk or its suitability as a complete or partial substitute for human milk".Manufacturers state that the composition of infant formula is designed to be roughly based on a human mother's milk at approximately one to three months postpartum; however, there are significant differences in the nutrient content of these products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Food_pyramid_(nutrition)">Food pyramid (nutrition)</a></td>
      <td>A food pyramid is a representation of the optimal number of servings to be eaten each day from each of the basic food groups. The first pyramid was published in Sweden in 1974.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minsk_agreements">Minsk agreements</a></td>
      <td>The Minsk agreements were a series of international agreements which sought to end the war in the Donbas region of Ukraine. The first, known as the Minsk Protocol, was drafted in 2014 by the Trilateral Contact Group on Ukraine, consisting of Ukraine, Russia, and the Organization for Security and Co-operation in Europe (OSCE), with mediation by the leaders of France and Germany in the so-called Normandy Format.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Good_Friday_Agreement">Good Friday Agreement</a></td>
      <td>The Good Friday Agreement (GFA), or Belfast Agreement (Irish: Comhaontú Aoine an Chéasta or Comhaontú Bhéal Feirste; Ulster-Scots: Guid Friday Greeance or Bilfawst Greeance), is a pair of agreements signed on 10 April 1998 that ended most of the violence of the Troubles, a political conflict in Northern Ireland that had ensued since the late 1960s. It was a major development in the Northern Ireland peace process of the 1990s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Infant_nutrition">Infant nutrition</a></td>
      <td>Infant nutrition is the description of the dietary needs of infants. A diet lacking essential calories, minerals, vitamins, or fluids is considered inadequate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Omega_Psi_Phi_chapters">List of Omega Psi Phi chapters</a></td>
      <td>Omega Psi Phi (ΩΨΦ) is an international historically Black fraternity. Founded on November 17, 1911 at Howard University in Washington, D.C., Omega Psi Phi has chartered chapters at various colleges, universities and cities.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Opel_Omega">Opel Omega</a></td>
      <td>The Opel Omega is an executive car engineered and manufactured by German automaker Opel between 1986 and 2004. The first generation, the Omega A (1986–1993), superseded the Opel Rekord.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Omega_Delta_Phi">Omega Delta Phi</a></td>
      <td>Omega Delta Phi Fraternity Inc. (ΩΔΦ), also known as O-D-Phi is a multicultural fraternity that was founded on November 25, 1987, at Texas Tech University in Lubbock, Texas.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Star_Wars:_The_Bad_Batch">Star Wars: The Bad Batch</a></td>
      <td>Star Wars: The Bad Batch is an American animated series created by Dave Filoni for the streaming service Disney+. It is part of the Star Wars franchise, acting as both a sequel to, and spin-off from, the series Star Wars: The Clone Wars.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gamma_World">Gamma World</a></td>
      <td>Gamma World is a science fantasy role-playing game, originally designed by James M. Ward and Gary Jaquet, and first published by TSR in 1978.  It borrowed heavily from Ward's earlier game, Metamorphosis Alpha.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Virginia_Tech">Virginia Tech</a></td>
      <td>Virginia Tech (formally the Virginia Polytechnic Institute and State University and informally VT, VA Tech or VPI) is a public land-grant research university with its main campus in Blacksburg, Virginia. It also has educational facilities in six regions statewide, a research center in Punta Cana, Dominican Republic, and a study-abroad site in Riva San Vitale, Switzerland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lotus_Carlton">Lotus Carlton</a></td>
      <td>The Lotus Carlton (also called Vauxhall Lotus Carlton, Lotus Omega and Opel Lotus Omega) is a Vauxhall Carlton/Opel Omega A saloon upgraded by Lotus in order to be able to reach speeds up to 285 km/h (177 mph) with acceleration to equal contemporary sports cars. Like all Lotus vehicles, it was given a type designation—Type 104 in this case.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statement_of_Assets,_Liabilities,_and_Net_Worth">Statement of Assets, Liabilities, and Net Worth</a></td>
      <td>A Statement of Assets, Liabilities, and Net Worth (SALN) is an annual document that all government workers in the Philippines, whether regular or temporary, must complete and submit attesting under oath to their total assets and liabilities, including businesses and financial interests, that make up their net worth.  The assets and liabilities of the official, his or her spouse, and any unmarried children under 18 who are living at home, must be included.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Contingent_liability">Contingent liability</a></td>
      <td>Contingent liabilities are liabilities that may be incurred by an entity depending on the outcome of an uncertain future event such as the outcome of a pending lawsuit. These liabilities are not recorded in a company's accounts and shown in the balance sheet when both probable and reasonably estimable as 'contingency' or 'worst case' financial outcome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limited_liability_company">Limited liability company</a></td>
      <td>A limited liability company (LLC) is the US-specific form of a private limited company. It is a business structure that can combine the pass-through taxation of a partnership or sole proprietorship with the limited liability of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Liability">The Liability</a></td>
      <td>The Liability (also known as The Hitman's Apprentice) is a 2013 British black comedy crime-thriller film directed by Craig Viveiros and written by John Wrathall. The film stars Tim Roth, Talulah Riley, Jack O'Connell and Peter Mullan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Legal_liability">Legal liability</a></td>
      <td>In law, liable means  "responsible or answerable in law; legally obligated". Legal liability concerns both civil law and criminal law and can arise from various areas of law, such as contracts, torts, taxes, or fines given by government agencies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Thraustochytrids">Thraustochytrids</a></td>
      <td>Thraustochytrids are single-celled saprotrophic eukaryotes (decomposers) that are widely distributed in marine ecosystems, and which secrete enzymes including, but not limited to amylases, proteases, phosphatases. They are most abundant in regions with high amounts of detritus and decaying plant material.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Eugene_Rotberg">Eugene Rotberg</a></td>
      <td>Gene Rotberg, a lawyer and international investment banker, is an expert on risk taking, interest and exchange rates, financial market regulation, and the role of international development institutions. He served as vice president and treasurer of the World Bank from 1968 to 1987, responsible for overall funding and investment operations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/William_E._Bentley">William E. Bentley</a></td>
      <td>William E. Bentley is the Robert E. Fischell Distinguished Professor of Engineering, founding Director of the Fischell Institute for Biomedical Devices, and Director of the Maryland Technology Enterprise Institute located in the A. James Clark School of Engineering at the University of Maryland. He was previously the Chair of the Fischell Department of Bioengineering, where he assisted in establishing the department and provided leadership that led to its nationally ranked status.Dr.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alan_Walton">Alan Walton</a></td>
      <td>Alan G. Walton OBE (April 3, 1936 – July 4, 2015) was a scientist, businessman, and venture capitalist. He was born in England in 1936 and earned a Ph.D. from the University of Nottingham.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Before making an     <font color="blue"><font color="blue">investment</font> decision</font>, you <font color="blue">should carefully</font> consider the <font color="blue">risk factors set</font>     forth herein, as well as other information we include in this report and the     <font color="blue">additional</font> information in the other reports we file with the <font color="blue">Securities </font>and     Exchange Commission (the “SEC” or the “Commission”)</td>
    </tr>
    <tr>
      <td>In such case, the     <font color="blue">trading price</font> of our <font color="blue">securities could decline</font> and you <font color="blue">could lose</font> all or part     of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>You should be cautioned that the <font color="blue">following important factors</font> have affected,     and  in the <font color="blue">future could affect</font>, our actual results</td>
    </tr>
    <tr>
      <td>There may also be     <font color="blue">additional</font> factors not discussed in this report that <font color="blue">could also affect</font>     future results</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> cause our <font color="blue">future financial</font> results to     <font color="blue">differ <font color="blue">materially</font> from</font> those expressed in any forward-looking statements     made by us</td>
    </tr>
    <tr>
      <td>Forward-looking <font color="blue">statements may</font> relate to <font color="blue">such matters as</font>:       •   our ability to <font color="blue">generate future revenues</font>;         •   the <font color="blue">commercialization</font> of our products;         •   the expansion and <font color="blue">ongoing operation</font> of <font color="blue">facilities</font> producing our     products;         •   our ability to produce <font color="blue">adequate amounts</font> of our <font color="blue">products ourselves</font> or     through third-party <font color="blue">manufacture</font>rs;         •   the <font color="blue">optimization</font> of <font color="blue">production costs</font>; and         •   our ability to <font color="blue">enter into future</font> business <font color="blue">collaborations</font> and marketing     <font color="blue">partnerships</font></td>
    </tr>
    <tr>
      <td>Forward-looking <font color="blue">statements may</font> include words such as “will,” “should,”     “could,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,”     and other similar <font color="blue">expressions</font></td>
    </tr>
    <tr>
      <td>This list does not <font color="blue">constitute</font> all factors     which  you should consider prior to making a decision to invest in our     securities</td>
    </tr>
    <tr>
      <td>You <font color="blue">should also</font> not assume that the information <font color="blue">contained herein</font>     is complete or accurate in all respects after the date of this filing</td>
    </tr>
    <tr>
      <td>We     disclaim any duty to update the statements <font color="blue">contained herein</font></td>
    </tr>
    <tr>
      <td>A substantial portion of our <font color="blue"><font color="blue">nutritional oil products</font> sales</font> is made to four     of  our  existing  <font color="blue">customers under <font color="blue"><font color="blue">agreement</font>s</font> with no <font color="blue">minimum purchase</font></font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">demand by</font> these customers for our <font color="blue">nutritional oil products</font>     declines, our <font color="blue">revenues may <font color="blue">materially</font> decline</font></td>
    </tr>
    <tr>
      <td>We  rely  on a substantial portion of our <font color="blue">product sales</font> to four of our     <font color="blue">existing customers</font></td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>88prca of our <font color="blue">product sales</font> revenue during     the year ended October 31, 2005 was <font color="blue">generated by sales</font> of <font color="blue">DHA and ARA </font>to     four customers, <font color="blue">Mead Johnson </font>Nutritionals, Abbott Laboratories, Nestle and     Wyeth</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that these <font color="blue">customers <font color="blue">will continue</font></font> to demand our     <font color="blue"><font color="blue">nutritional products</font> at current</font> or <font color="blue">predictable levels</font></td>
    </tr>
    <tr>
      <td>None of our license     <font color="blue"><font color="blue">agreement</font>s</font> requires our licensees to purchase any minimum amount of products     from us now or in the future, and certain of our license <font color="blue"><font color="blue">agreement</font>s</font> allow     our licensees to <font color="blue">manufacture</font> our <font color="blue">products <font color="blue">themselves</font></font> or <font color="blue">purchase nutritional</font>     oils from other sources</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">visibility into</font> our customers’     <font color="blue">future actual level</font> of demand, notwithstanding our view of <font color="blue">consumer demand</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">demand by</font> any of our <font color="blue"><font color="blue">significant</font> customers</font> for our <font color="blue">nutritional products</font>     declines, we may experience a material decline in our revenues</td>
    </tr>
    <tr>
      <td>We are aware of <font color="blue">several products</font> that are <font color="blue">currently available</font>, and products     <font color="blue">under <font color="blue">development</font></font>, that <font color="blue">may present</font> a <font color="blue">serious <font color="blue">competitive</font> threat</font> to our     products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends upon</font> achieving and maintaining a superior <font color="blue">competitive</font>     position in the <font color="blue">infant formula</font> and <font color="blue">adult nutritional product markets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>potential <font color="blue">competitors</font>, which include <font color="blue">companies such as</font> BASF AG, Cargill     Inc, Suntory Limited, Celanese Corporation, Lonza Group LTD and Nagase &amp;     Co</td>
    </tr>
    <tr>
      <td>Ltd, have <font color="blue">substantially greater research</font> and <font color="blue"><font color="blue">development</font> <font color="blue">capabilities</font></font>,     marketing,  financial  and  <font color="blue">managerial resources</font> and experience in the     industry</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">competitors</font> are currently offering competing sources     of <font color="blue">DHA and ARA </font>for use in the <font color="blue">adult market</font> and for use in <font color="blue">infant formula</font>     outside the US If a competitor develops a better product or <font color="blue">technology</font>,     our  <font color="blue">competitors</font>’  products gain widespread <font color="blue">acceptance</font>, or we lose our     patents, the sales of our products may be <font color="blue">materially</font> <font color="blue">adversely</font> affected and     our <font color="blue">technologies</font> rendered obsolete</td>
    </tr>
    <tr>
      <td>We are aware that other sources of <font color="blue">DHA and ARA </font>are, or may, be available,     any of <font color="blue">which could represent</font> a <font color="blue">competitive</font> threat that <font color="blue">could seriously harm</font>     our <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>Specifically:       •   the Ross Products Division of Abbott Laboratories, a <font color="blue">significant</font>     Martek licensee and customer, filed a <font color="blue">generally</font> recognized as safe     <font color="blue"><font color="blue">notification</font> on</font> January 2, 2002 seeking Food and Drug Administration     (“FDA”) <font color="blue">concurrence</font> that its <font color="blue">fish oil source</font> of DHA and its <font color="blue">fungal source</font> of     ARA are <font color="blue">generally</font> recognized as safe when <font color="blue">used <font color="blue">as ingredients</font></font> in infant     formula</td>
    </tr>
    <tr>
      <td>At this time, the <font color="blue"><font color="blue">notification</font> continues</font> to be <font color="blue">under <font color="blue">consideration</font></font>     by the FDA;         •   Reliant Pharmaceuticals launched Omacor, a DHA/ EPA <font color="blue">ethyl ester</font>, in     the  second  half of 2005 for treatment of <font color="blue">hyperlipidemia</font></td>
    </tr>
    <tr>
      <td>Omacor is a     lipid-regulating agent which includes both <font color="blue">EPA and DHA </font><font color="blue">from fish oil</font></td>
    </tr>
    <tr>
      <td>We     expect <font color="blue">additional</font> studies to expand the <font color="blue">approved indications</font> for Omacor</td>
    </tr>
    <tr>
      <td>•   Suntory Limited, Cargill Inc, through a <font color="blue">joint venture with</font> a company     in China, and other <font color="blue">independent</font> Chinese <font color="blue">manufacture</font>rs are producing and     <font color="blue">distributing</font> a <font color="blue">fungal source</font> of ARA In addition, we are aware that there     may be <font color="blue">manufacture</font>rs in China attempting to produce an <font color="blue">algal source</font> of DHA,     but we are uncertain of the <font color="blue">overall status</font> and <font color="blue">commercial potential</font> of these     <font color="blue"><font color="blue">development</font> efforts</font>;                                         19       _________________________________________________________________             •   some <font color="blue">infant formula</font>s now on the <font color="blue">market outside</font> the <font color="blue"><font color="blue">United States</font> </font>use     DHA <font color="blue">derived from</font> other sources, such as fish oil or eggs;          •     Nutrinova  Nutrition  Specialties  &amp; Food Ingredients GmbH, a     wholly-owned subsidiary of Celanese Corporation, has <font color="blue">been actively marketing</font>     a DHA-rich <font color="blue">microalgal oil</font> to the food and beverage and <font color="blue">dietary supplement</font>     markets in the <font color="blue">United States</font>, China and Europe</td>
    </tr>
    <tr>
      <td>We have filed a patent     infringement suit against Nutrinova in both the <font color="blue"><font color="blue">United States</font> </font>and Germany</td>
    </tr>
    <tr>
      <td>in  Item 1A  Risk  Factors  and in our various other <font color="blue">filings with</font> the     <font color="blue">Securities </font>and Exchange Commission</td>
    </tr>
    <tr>
      <td>Our forward-looking statements speak     only as of the date of this document, and we do not intend to update these     statements to <font color="blue">reflect events</font> or <font color="blue">circumstances</font> that occur after that date</td>
    </tr>
    <tr>
      <td>We are a leader in the <font color="blue">development</font> and     <font color="blue">commercialization</font> of products <font color="blue">derived from</font> microalgae, fungi and other     microbes</td>
    </tr>
    <tr>
      <td>Our <font color="blue">leading products</font> are <font color="blue">nutritional oils</font> <font color="blue">used <font color="blue">as ingredients</font></font> in     infant  formula  and  foods  and  beverages and <font color="blue">as ingredients</font> in, and     <font color="blue">encapsulated</font> for use as, <font color="blue">dietary supplement</font>s</td>
    </tr>
    <tr>
      <td>Our <font color="blue">nutritional oils</font> are     comprised of fatty acid components, primarily docosahexaenoic acid, commonly     known as DHA, and <font color="blue">arachidonic</font> acid, commonly known as <font color="blue">ARA Research </font>has     shown that these <font color="blue">fatty acids may enhance mental</font> and visual <font color="blue">development</font> in     infants, that they may play a <font color="blue">pivotal role</font> in <font color="blue">brain function throughout</font>     life, and that they may reduce the risk of <font color="blue">cardiovascular disease</font></td>
    </tr>
    <tr>
      <td>Low     levels of DHA in adults have been linked to a variety of <font color="blue">health risks</font>,     including Alzheimer’s disease</td>
    </tr>
    <tr>
      <td>Further research is underway to assess the     role  of  <font color="blue">supplementation</font>  with  our DHA on a variety of <font color="blue">health risks</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue"><font color="blue">application</font>s</font> of our patented <font color="blue">technology</font> based upon microalgae     include our <font color="blue">currently marketed <font color="blue">fluorescent detection</font> products</font> that can be     <font color="blue">used by researchers as</font> an aid in <font color="blue">drug discovery</font> and <font color="blue">diagnostics</font></td>
    </tr>
    <tr>
      <td>In 1992, we realized our <font color="blue">first <font color="blue">revenues from</font> license fees</font> related to our     <font color="blue">nutritional oils</font> containing <font color="blue">DHA and ARA </font>and sales of sample quantities of     these oils</td>
    </tr>
    <tr>
      <td>In 1995, we recognized our <font color="blue">first product</font> and <font color="blue">royalty revenues</font>     from sales of <font color="blue">infant formula</font> containing these oils, and in 1996 we began to     realize <font color="blue">revenues from</font> the sale of Neuromins^®, a DHA <font color="blue">dietary supplement</font></td>
    </tr>
    <tr>
      <td>In     1998, we first realized <font color="blue">revenues from</font> the sale of our <font color="blue">fluorescent detection</font>     products</td>
    </tr>
    <tr>
      <td>In 2001, the FDA completed a favorable review of our <font color="blue">generally</font>     recognized <font color="blue">as safe <font color="blue">notification</font></font> for the use of our <font color="blue">DHA and ARA </font>oil blend in     <font color="blue">specified ratios</font> in <font color="blue">infant formula</font></td>
    </tr>
    <tr>
      <td>We have entered into license <font color="blue"><font color="blue">agreement</font>s</font>     with  21  infant  formula  <font color="blue">manufacture</font>rs,  who  <font color="blue"><font color="blue">collectively</font> represent</font>     <font color="blue">approximately</font> 70prca of the estimated dlra8dtta5 to dlra9dtta5 billion worldwide wholesale     market  for  infant  formula  and nearly 100prca of the estimated dlra3dtta0 to     dlra3dtta5 billion  US  <font color="blue">wholesale market</font> for <font color="blue">infant formula</font>, including the     <font color="blue">wholesale value</font> of Women, Infant &amp; Children program (“WIC”) rebates</td>
    </tr>
    <tr>
      <td>WIC is     a  <font color="blue">federal grant program administered by</font> the states for the benefit of     low-income, nutritionally at-risk women, infants and children</td>
    </tr>
    <tr>
      <td>Our licensees     include <font color="blue">infant formula</font> market leaders <font color="blue">Mead Johnson </font>Nutritionals, Nestle,     Abbott Laboratories, Wyeth and Royal Numico, each of whom is <font color="blue">selling infant</font>     <font color="blue">formula fortified with</font> our <font color="blue">nutritional oils</font></td>
    </tr>
    <tr>
      <td>Our licensees are now selling     term <font color="blue">infant formula</font> products containing our oils <font color="blue">collectively</font> in over 30     countries  and  pre-term  infant  <font color="blue">formula products containing</font> our oils     <font color="blue">collectively</font> in over 60 countries around the world</td>
    </tr>
    <tr>
      <td><font color="blue">Supplemented </font>term infant     formulas <font color="blue">manufacture</font>d by <font color="blue">Mead Johnson </font>Nutritionals, Abbott Laboratories,     Wyeth and Nestle are currently being sold in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>33       _________________________________________________________________           In  April 2002,  we  acquired  OmegaTech, Inc</td>
    </tr>
    <tr>
      <td>(“OmegaTech” or “Martek     Boulder”), a low-cost algal DHA <font color="blue">producer located</font> in Boulder, Colorado</td>
    </tr>
    <tr>
      <td><font color="blue">OmegaTech </font>had been in the <font color="blue">fermentable</font> DHA business since 1987, and had     <font color="blue"><font color="blue">accumulate</font>d</font>  over  100  issued  and <font color="blue">pending patents protecting</font> its DHA     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Its <font color="blue">revenues mainly consisted</font> of sales of DHA into the dietary     supplement and <font color="blue"><font color="blue">animal feed</font> markets</font></td>
    </tr>
    <tr>
      <td>We acquired <font color="blue">OmegaTech </font>to obtain its     low-cost DHA oil and related <font color="blue">intellectual property</font> for use in the adult     <font color="blue"><font color="blue">supplements</font> market</font> and <font color="blue">future use</font> in the food and <font color="blue">beverage markets</font></td>
    </tr>
    <tr>
      <td>In June 2002, the <font color="blue">Australia New Zealand Food Standards Council </font>authorized     the use of DHA-S oil for use as a <font color="blue">Novel Food </font>ingredient in Australia and New     Zealand</td>
    </tr>
    <tr>
      <td>In June 2003, the <font color="blue">European Commission </font>authorized the use of our     DHA-S  oil and declared that our DHA-S oil may be sold in the European     Community as a <font color="blue">Novel Food </font>ingredient</td>
    </tr>
    <tr>
      <td>This <font color="blue">Novel Food </font><font color="blue">designation authorizes</font>     the use of our DHA-S as an ingredient in <font color="blue"><font color="blue">certain foods</font> such as certain dairy</font>     products, including cheese and yogurt (but not milk-based drinks), spreads     and dressings, breakfast cereals, food <font color="blue">supplements</font> and <font color="blue">dietary foods</font> for     <font color="blue">special medical purposes</font> in the <font color="blue">European Community</font></td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2004, the     FDA completed a favorable review of our GRAS <font color="blue">notification</font> for the use of     DHA-S in food and beverage <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently selling</font> DHA-S     products  in the <font color="blue">dietary supplement</font>, food and beverage and <font color="blue">animal feed</font>     <font color="blue">markets domestically</font> and <font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td>In  September 2003,  we  purchased  certain assets and assumed certain     <font color="blue">liabilities</font> of FermPro Manufacturing, LP, which operated a <font color="blue">fermentation</font>     <font color="blue"><font color="blue">facility</font> located</font> in Kingstree, South Carolina</td>
    </tr>
    <tr>
      <td>FermPro <font color="blue">provided contract</font>     <font color="blue">fermentation</font> services and had an experienced workforce of over 100 personnel     on  a  site  of  over 500 acres with extensive <font color="blue">fermentation</font>, recovery,     <font color="blue">laboratory</font>  and  <font color="blue">warehousing <font color="blue">capabilities</font></font></td>
    </tr>
    <tr>
      <td>The addition of the <font color="blue">FermPro     </font><font color="blue">facility</font> and workforce has <font color="blue">enabled us</font> to expand our <font color="blue">production <font color="blue">capabilities</font></font>     through the existing <font color="blue">facility</font>, as well as the <font color="blue">significant</font> plant expansion     that was completed in fiscal 2005</td>
    </tr>
    <tr>
      <td>During the past two years, several new products were launched that contained     <font color="blue">Martek DHA</font>™, including:       •   <font color="blue">Mead Johnson </font>launched Expecta™ LIPIL^®, a DHA supplement for pregnant     and <font color="blue"><font color="blue">nursing women</font> containing</font> <font color="blue">Martek DHA</font>™</td>
    </tr>
    <tr>
      <td>•   <font color="blue">PBM Products </font>launched a <font color="blue">beverage containing</font> <font color="blue">Martek DHA</font>™ that is     formulated for <font color="blue">diabetics</font> and people <font color="blue">with atypical glucose tolerance</font></td>
    </tr>
    <tr>
      <td>•   <font color="blue">GlaxoSmithKline </font>launched a <font color="blue">second powdered drink mix containing</font> Martek     DHA™ in India</td>
    </tr>
    <tr>
      <td>The product, Junior Horlicks, is formulated for a child’s     developing brain and <font color="blue">nervous system</font></td>
    </tr>
    <tr>
      <td><font color="blue">GlaxoSmithKline </font>has <font color="blue">previously launched</font>     an adult DHA beverage</td>
    </tr>
    <tr>
      <td>•   First Horizon Pharmaceutical^® has <font color="blue">recently launched</font> OptiNate™ and     <font color="blue">Mission Pharmacal </font><font color="blue">will soon launch</font> CITRICAL^® Prenatal + DHA Both of these     products are <font color="blue">prescription</font> prenatal <font color="blue">supplements</font> containing <font color="blue">Martek DHA</font>™</td>
    </tr>
    <tr>
      <td>•     Vincent Foods, LLC has <font color="blue">begun offering</font> Oh Mama!</td>
    </tr>
    <tr>
      <td><font color="blue">nutrition bars</font>     containing <font color="blue">Martek DHA</font>™, <font color="blue">which also target pregnant</font> and <font color="blue">nursing women</font></td>
    </tr>
    <tr>
      <td>•   Several <font color="blue">egg producers</font>, including Gold Circle Farms^®, are now offering     eggs and <font color="blue">liquid eggs using</font> <font color="blue">Martek DHA</font>™</td>
    </tr>
    <tr>
      <td>These eggs are sold in several     <font color="blue">grocery store chains</font> in the US and Europe</td>
    </tr>
    <tr>
      <td>•   Priegola has launched Simbi + Omega-3 <font color="blue">yogurt with</font> <font color="blue">Martek DHA</font>™, which     is now available in <font color="blue">major supermarket chains throughout</font> Spain and is being     marketed to children and adults for its brain health benefits</td>
    </tr>
    <tr>
      <td>All of these products are expected to generate <font color="blue">additional</font> revenue for us     during fiscal 2006</td>
    </tr>
    <tr>
      <td>For  the  years  ended  October 31, 2005, 2004 and 2003, we recognized     <font color="blue">approximately</font> dlra15dtta3 million, dlra47dtta0 million and dlra16dtta0 million of net income,     <font color="blue">respectively</font>,  and as of October 31, 2005, our <font color="blue"><font color="blue">accumulate</font>d</font> deficit was     <font color="blue">approximately</font> dlra49dtta2 million</td>
    </tr>
    <tr>
      <td>Although we anticipate <font color="blue">continued growth</font> in     <font color="blue">annual sales</font> of our <font color="blue">nutritional oils</font>, and we have achieved an operating     profit in each of the <font color="blue">last three fiscal years</font>, we <font color="blue">may continue</font> to experience     quarter-to-quarter and year-to-year fluctuations in our future operating     results, some of which may be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>The timing and extent of such     <font color="blue">fluctuations will depend</font>, in part, on the timing and receipt of oils-related     revenues</td>
    </tr>
    <tr>
      <td>The timing and extent of future oils-related revenues are largely     <font color="blue">dependent upon</font> the <font color="blue">following factors</font>:       •   the timing of <font color="blue">infant formula</font> market <font color="blue">introductions</font> by our licensees     <font color="blue">both domestically</font> and <font color="blue">internationally</font>;         •   the timing and extent of stocking and destocking of <font color="blue">inventory by</font> our     licensees, including the potential that <font color="blue">licensees will</font> move to “just in     time” <font color="blue">inventory purchasing</font> now that we have reached a base finished goods     <font color="blue">inventory level</font>;         •   the timing and extent of <font color="blue">introductions</font> of DHA <font color="blue">into various child</font>     and/or adult <font color="blue"><font color="blue">application</font>s</font>;          •    the continued <font color="blue">acceptance</font> of products containing our oils under     state-administered reimbursement programs in the US;         •   the continued <font color="blue">acceptance</font> of these products by consumers and continued     <font color="blue">demand by</font> our customers;         •   the ability by us, DSM and other third-party <font color="blue">manufacture</font>rs to produce     <font color="blue">adequate levels</font> of our <font color="blue">nutritional oils</font> on a <font color="blue">consistent basis</font>;          •   our ability to protect against <font color="blue">competitive</font> products through our     patents;         •   <font color="blue"><font color="blue">competition</font> from alternative sources</font> of DHA and ARA; and         •   <font color="blue"><font color="blue">agreement</font>s</font> with other future third-party <font color="blue">collaborators</font> to market our     products or develop new products</td>
    </tr>
    <tr>
      <td>As such, the likelihood, timing and extent of <font color="blue">future profitability</font> are     <font color="blue">largely dependent on factors such as</font> those mentioned above, as well as     others, over which we have limited or no control</td>
    </tr>
    <tr>
      <td>34       _________________________________________________________________                              CRITICAL ACCOUNTING POLICIES AND                              THE USE OF ESTIMATES       The <font color="blue">preparation</font> of our <font color="blue">consolidated financial statements</font> in <font color="blue">conformity with</font>     US <font color="blue">generally</font> accepted accounting principles requires <font color="blue">management</font> to make     estimates  and  <font color="blue">assumptions</font>  that  affect  the amounts reported in our     <font color="blue">consolidated financial statements</font> and <font color="blue">accompanying</font> notes</td>
    </tr>
    <tr>
      <td>On an ongoing     basis,  we  evaluate  our  estimates and judgments, which are <font color="blue">based on</font>     historical  and  anticipated  results  and trends and on various other     <font color="blue">assumptions</font>  that  we  believe are reasonable under the <font color="blue">circumstances</font>,     including <font color="blue">assumptions</font> as to future events</td>
    </tr>
    <tr>
      <td>By their nature, estimates are     subject to an <font color="blue">inherent degree</font> of <font color="blue">uncertainty</font> and, as such, actual results     <font color="blue">may differ from</font> our estimates</td>
    </tr>
    <tr>
      <td>We believe that the following <font color="blue">significant</font>     <font color="blue">accounting policies</font> and <font color="blue">assumptions</font> involve a <font color="blue">higher degree</font> of judgment and     <font color="blue">complexity than others</font></td>
    </tr>
    <tr>
      <td>Valuation of Long-lived Assets We review our long-lived assets, including     fixed assets and certain identified <font color="blue">intangibles</font>, for <font color="blue"><font color="blue">impairment</font> as events</font> or     changes in <font color="blue">circumstances</font> occur indicating that the carrying amount of the     asset may not be recoverable</td>
    </tr>
    <tr>
      <td><font color="blue">As of October </font>31, 2005, these long-lived     assets had a <font color="blue">total net book value</font> of dlra321dtta9 million</td>
    </tr>
    <tr>
      <td>Included in these     long-lived assets are <font color="blue">approximately</font> dlra37dtta5 million of qualified production     equipment  whose use is not currently required due to excess <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td><font color="blue">Undiscounted </font><font color="blue">cash flow analyses</font> are used to <font color="blue">assess <font color="blue">impairment</font></font></td>
    </tr>
    <tr>
      <td>The estimates     of future cash flows involve considerable <font color="blue">management</font> judgment and are based     upon  <font color="blue">assumptions</font>  about  expected future operating performance</td>
    </tr>
    <tr>
      <td><font color="blue">While     </font><font color="blue">management</font>  believes  that  its <font color="blue">projections</font> are reasonable and that no     <font color="blue">impairment</font> of these assets exists, different <font color="blue">assumptions</font> could affect these     <font color="blue">evaluations</font> and result in material <font color="blue">impairment</font> charges against the carrying     value of these assets</td>
    </tr>
    <tr>
      <td><font color="blue">Revenue Recognition We </font>derive revenue principally from two sources: product     sales and <font color="blue">contract manufacturing</font></td>
    </tr>
    <tr>
      <td>We recognize revenue when persuasive     evidence  of  an <font color="blue">arrangement</font> exists, the fee is fixed or <font color="blue">determinable</font>,     <font color="blue">collectibility</font> is probable and the product is <font color="blue">shipped thereby transferring</font>     title and risk of loss</td>
    </tr>
    <tr>
      <td>Typical <font color="blue">infant formula</font> license contracts include an     <font color="blue">upfront license fee</font>, a <font color="blue">prepayment</font> of <font color="blue">product sales</font> and <font color="blue">established pricing</font>     on future <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>In <font color="blue"><font color="blue">accordance</font> with</font> Emerging Issues Task Force     Nodtta 00-21  (“EITF  Nodtta 00-21”),  “Revenue  Arrangements  with Multiple     Deliverables,” the <font color="blue">consideration</font> from these contracts is allocated <font color="blue">based on</font>     the relative <font color="blue">fair value</font>s of the <font color="blue">separate elements</font></td>
    </tr>
    <tr>
      <td>Revenue is recognized on     <font color="blue">product sales</font> when goods are shipped and all other <font color="blue">conditions</font> for revenue     <font color="blue">recognition</font>  are  met</td>
    </tr>
    <tr>
      <td>Cash received as a <font color="blue">prepayment</font> on future product     purchases is deferred and recognized as revenue when product is shipped</td>
    </tr>
    <tr>
      <td>Revenue <font color="blue">from product licenses</font> is deferred and recognized on a straight-line     basis  over the term of the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Royalty income is recorded when     earned, <font color="blue">based on</font> information <font color="blue">provided by</font> our licensees</td>
    </tr>
    <tr>
      <td>Contract <font color="blue">manufacturing revenue</font> is recognized when goods are shipped to     customers and all other <font color="blue">conditions</font> for revenue <font color="blue">recognition</font> are met</td>
    </tr>
    <tr>
      <td><font color="blue">Cash     </font>received that is related to <font color="blue">future performance under such contracts</font> is     deferred and recognized as revenue when earned</td>
    </tr>
    <tr>
      <td><font color="blue">Deferred Income Taxes We </font>provide for <font color="blue">income taxes</font> in <font color="blue"><font color="blue">accordance</font> with</font> the     <font color="blue">liability method</font></td>
    </tr>
    <tr>
      <td>Under this method, <font color="blue">deferred tax</font> assets and <font color="blue">liabilities</font> are     determined <font color="blue"><font color="blue">based on</font> differences between</font> the financial reporting bases and     the tax bases of assets and <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>We also recognize <font color="blue">deferred tax</font>     assets for <font color="blue">certain tax net</font> operating <font color="blue">loss carryforwards</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">deferred tax</font>     assets and <font color="blue">liabilities</font> are <font color="blue">measured using</font> the <font color="blue">enacted tax rates</font> and laws     that will be in effect when <font color="blue">such amounts</font> are expected to reverse or be     utilized</td>
    </tr>
    <tr>
      <td><font color="blue">As of October </font>31, 2005, our total gross <font color="blue">deferred tax</font> asset was     dlra73dtta5 million</td>
    </tr>
    <tr>
      <td>The <font color="blue">realization</font> of <font color="blue">deferred tax</font> assets is <font color="blue">contingent upon</font> the     <font color="blue">generation</font>  of <font color="blue">future taxable income</font></td>
    </tr>
    <tr>
      <td>When <font color="blue">appropriate</font>, we recognize a     <font color="blue">valuation allowance</font> to reduce such <font color="blue">deferred tax</font> assets to amounts that are     more <font color="blue">likely than</font> not to be ultimately realized</td>
    </tr>
    <tr>
      <td>The <font color="blue">calculation</font> of deferred     tax  assets  (including <font color="blue">valuation allowance</font>s) and <font color="blue">liabilities</font> requires     <font color="blue">management</font> to apply <font color="blue">significant</font> judgment related to <font color="blue">such factors as</font> the     <font color="blue">application</font>  of  complex  tax laws, changes in tax laws and the future     <font color="blue">operations</font> of the Company</td>
    </tr>
    <tr>
      <td>We review our <font color="blue">deferred tax</font> assets on a quarterly     basis to determine if a change to our <font color="blue">valuation allowance</font> is required based     upon these factors</td>
    </tr>
    <tr>
      <td><font color="blue">As of October </font>31, 2005, our <font color="blue">deferred tax</font> asset valuation     allowance  was  dlra23dtta8  million, which related primarily to <font color="blue">certain net</font>     operating <font color="blue">loss carryforwards</font> whose <font color="blue">realization</font> is uncertain</td>
    </tr>
    <tr>
      <td>Changes in our     <font color="blue">assessment</font> of the need for a <font color="blue">valuation allowance</font> could give rise to a change     in such allowance, <font color="blue">potentially</font> resulting in material amounts of <font color="blue">additional</font>     expense or benefit in the period of change</td>
    </tr>
    <tr>
      <td>Inventory  We  carry  our <font color="blue">inventory at</font> the lower of cost or market</td>
    </tr>
    <tr>
      <td>We     <font color="blue">regularly review inventory quantities on hand</font> and record a reserve for     excess, obsolete and “off-spec” inventory based primarily on an estimated     forecast of <font color="blue">product demand</font> and the likelihood of <font color="blue">consumption</font> in the normal     course of manufacturing <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Those reserves are <font color="blue">based on</font> <font color="blue">significant</font>     estimates</td>
    </tr>
    <tr>
      <td>Our estimates of future <font color="blue">product demand</font> or <font color="blue">assessment</font>s of future     <font color="blue">consumption</font>  may  prove  to  be  <font color="blue">inaccurate</font>, in which case we may have     understated or overstated the provision required</td>
    </tr>
    <tr>
      <td>Although we make every     effort  to  ensure  the accuracy of our forecasts and <font color="blue">assessment</font>s, any     <font color="blue">significant</font> unanticipated changes, <font color="blue">particularly</font> in demand or <font color="blue">competition</font>     levels, could have a <font color="blue">significant</font> impact on the values of our inventory and     our reported operating results</td>
    </tr>
    <tr>
      <td>Stock-Based Compensation We account for employee stock-based <font color="blue">compensation</font> in     <font color="blue">accordance</font>  with the provisions of Accounting Principles Board Opinion     Nodtta 25, “Accounting for Stock Issued to Employees” (“APB 25”) and related     interpretations, which require us to recognize <font color="blue"><font color="blue">compensation</font> cost</font> for the     excess of the <font color="blue">fair value</font> of the stock at the <font color="blue">grant date over</font> the exercise     price,  if  any</td>
    </tr>
    <tr>
      <td>An  <font color="blue">alternative method</font> of <font color="blue">accounting would apply</font> the     principles of SFAS Nodtta 123, “Accounting for Stock-Based Compensation” (“SFAS     123”), which require the <font color="blue">fair value</font> of the stock option to be recognized at     the date of grant and amortized to <font color="blue"><font color="blue">compensation</font> expense over</font> the stock     option’s vesting period</td>
    </tr>
    <tr>
      <td>No stock-based employee <font color="blue"><font color="blue">compensation</font> cost</font> for stock     options is reflected in net income, as all <font color="blue">options granted under</font> the plans     had an <font color="blue">exercise price</font> equal to the <font color="blue">market value</font> of the <font color="blue">underlying common</font>     stock on the date of grant</td>
    </tr>
    <tr>
      <td>Stock-based <font color="blue">compensation</font> for non-employees is     accounted for using the <font color="blue">fair value</font>-based method in <font color="blue"><font color="blue">accordance</font> with</font> SFAS 123</td>
    </tr>
    <tr>
      <td>See “Recently Issued Accounting Pronouncements</td>
    </tr>
    <tr>
      <td>”                                 MANAGEMENT OUTLOOK       From fiscal 2003 through early fiscal 2005, the demand for our nutritional     oils by our customers for use in <font color="blue">infant formula</font> products exceeded production     output and <font color="blue">capacity</font> and, as such, we limited the orders we accepted for our     <font color="blue">nutritional oils</font></td>
    </tr>
    <tr>
      <td>Some of our customers responded to the shortages and     inconsistent supply by building inventory, and we have had <font color="blue">difficulty</font> in     <font color="blue">predicting with certainty</font> our customers’ future ordering in light of limited     <font color="blue">visibility into</font> our customers’ supply chains and expansion plans</td>
    </tr>
    <tr>
      <td>To improve     <font color="blue">visibility into</font> our customers’ planned orders and to better understand the     <font color="blue">base level</font> of orders required to <font color="blue">meet current demand</font>, we have worked closely     with our customers to obtain new order <font color="blue">projections</font></td>
    </tr>
    <tr>
      <td><font color="blue">To                                         </font>35       _________________________________________________________________           address our <font color="blue">production output</font> and <font color="blue">capacity</font> issues, we and DSM have added     production <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>As a result, we are no longer limiting the orders we     accept  for  nutritional  oils, and, <font color="blue">furthermore</font>, we have been able to     <font color="blue">accumulate</font> and expect to maintain <font color="blue">DHA and ARA </font>finished goods <font color="blue">inventory at</font>     <font color="blue">levels which no longer constrain revenue growth</font></td>
    </tr>
    <tr>
      <td>We believe that the outlook for <font color="blue">future revenue growth remains</font> positive,     <font color="blue">although quarterly</font> results may show <font color="blue">significant</font> fluctuations</td>
    </tr>
    <tr>
      <td>Specifically,     we believe that over the <font color="blue">next twelve</font> to <font color="blue">eighteen months</font>, our <font color="blue">infant formula</font>     <font color="blue">product sales</font> in the US <font color="blue">market <font color="blue">will continue</font></font> to grow at a <font color="blue">measured pace</font>     <font color="blue">consistent with</font> the <font color="blue">consumer demand</font> growth for fortified <font color="blue">infant formula</font></td>
    </tr>
    <tr>
      <td><font color="blue">Expansion  </font>by  our  customers  <font color="blue">into new international markets offers</font> a     <font color="blue">potentially</font>  higher  growth  rate, but is subject to the timing of the     launches</td>
    </tr>
    <tr>
      <td>We also believe that we <font color="blue">will continue</font> to <font color="blue">gain market</font> share in     <font color="blue">existing international markets</font> and <font color="blue">new products containing</font> our oils will be     <font color="blue">launched by licensees</font></td>
    </tr>
    <tr>
      <td>In fiscal 2005, <font color="blue">approximately</font> 96prca of our <font color="blue">product sales</font> revenues related to     the sales of our oils for use in <font color="blue">infant formula</font>, pregnancy and nursing     <font color="blue">supplements</font> and <font color="blue">toddler products</font></td>
    </tr>
    <tr>
      <td>We anticipate <font color="blue">increased future sales</font> of     our oils for other <font color="blue">products such as foods</font> and beverages developed to promote     <font color="blue">cognitive function</font> and <font color="blue">cardiovascular health</font></td>
    </tr>
    <tr>
      <td>We expect that the majority of     these  sales will come through collaborative relationships with larger     companies in the nutritional and food and <font color="blue">beverage markets</font></td>
    </tr>
    <tr>
      <td>We anticipate     that over the <font color="blue">next few years</font>, these <font color="blue">sales will expand</font> and <font color="blue">could ultimately</font>     represent a larger potential market than <font color="blue">infant formula</font></td>
    </tr>
    <tr>
      <td>PRODUCTION       We <font color="blue">manufacture</font> oils rich in DHA at our <font color="blue">fermentation</font> and <font color="blue">oil processing</font>     <font color="blue">facilities</font> located in Winchester, Kentucky and Kingstree, South Carolina</td>
    </tr>
    <tr>
      <td>As     of  October 31, 2005, we have completed the extensive <font color="blue">expansion at</font> our     <font color="blue">Kingstree </font><font color="blue">facility</font> for the <font color="blue">fermentation</font> and processing of our nutritional     oils</td>
    </tr>
    <tr>
      <td>We have spent <font color="blue">approximately</font> dlra188 million on the <font color="blue">expansion since</font> the     inception of the project in fiscal 2003</td>
    </tr>
    <tr>
      <td>Our ARA oils are <font color="blue">purchased from</font> DSM as <font color="blue">manufacture</font>d at its Capua, Italy and     Belvidere, New Jersey plants</td>
    </tr>
    <tr>
      <td>DSM recently completed its expansion of its     ARA  <font color="blue">production <font color="blue">capabilities</font></font> at its <font color="blue">Belvidere </font><font color="blue">facility</font>, which has been     increasing  its <font color="blue">quarterly output</font></td>
    </tr>
    <tr>
      <td>This has <font color="blue">allowed us</font> to build our ARA     inventory  and  we  are  continuing to build this ARA inventory in the     short-term, until the <font color="blue">Belvidere </font><font color="blue">facility</font> exhibits more <font color="blue">consistent production</font>     performance</td>
    </tr>
    <tr>
      <td>We are now receiving <font color="blue">approximately</font> one-half of our ARA from     DSM’s <font color="blue">Belvidere </font><font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because DSM </font>is a third-party <font color="blue">manufacture</font>r, we do     not have full <font color="blue">control over</font> the timing and level of its Capua and <font color="blue">Belvidere </font>    <font color="blue">production volumes</font></td>
    </tr>
    <tr>
      <td><font color="blue">Annual ARA </font><font color="blue">pricing utilizes</font> a cost-plus <font color="blue">arrangement</font> and     is <font color="blue">based on</font> the prior year’s actual costs incurred adjusted for <font color="blue">current year</font>     <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Calendar </font>2005 ARA purchases have been valued by us <font color="blue">based on</font>     <font color="blue">pricing established through</font> this <font color="blue">methodology</font> and <font color="blue">invoiced from</font> DSM As part     of our April 2004 <font color="blue">agreement</font> with DSM, we are required to guarantee the     recovery to DSM of certain expansion costs incurred by them</td>
    </tr>
    <tr>
      <td>Our guarantee     to DSM which relates to their <font color="blue">phase one expansion</font> and was initially valued     at dlra8 million has <font color="blue">been eliminated through</font> ARA purchases in the <font color="blue">normal course</font>     of business</td>
    </tr>
    <tr>
      <td>In addition, we are in the process of <font color="blue">finalizing</font> an <font color="blue">amendment</font>     to the April 2004 <font color="blue">agreement</font> with DSM This <font color="blue">amendment</font>, among other things,     will  establish our guarantee of DSM’s <font color="blue"><font color="blue">phase two expansion</font> costs</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">guarantee will</font> have a <font color="blue">maximum value</font> of dlra40 million, with such amount being     <font color="blue">reduced annually through</font> <font color="blue">December </font>31, 2008 based upon ARA purchases in     excess of a <font color="blue">specified minimum threshold</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, this phase     <font color="blue">two proposed guarantee</font> has <font color="blue">been reduced</font> to <font color="blue">approximately</font> dlra32 million, with     this  reduction  occurring  primarily  in the <font color="blue">second half</font> of 2005 upon     <font color="blue">completion</font> of DSM’s <font color="blue">phase two expansion</font>     We have attempted to reduce the <font color="blue">risk inherent</font> in having a <font color="blue">single supplier</font>,     such as DSM, <font color="blue">through certain elements</font> of the supply <font color="blue">agreement</font> entered into     with <font color="blue">DSM in April </font>2004</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> this <font color="blue">agreement</font>, we have licensed     the DSM <font color="blue">technology</font> associated with ARA production</td>
    </tr>
    <tr>
      <td>Through this license and     the overall supply <font color="blue">arrangement</font>, we have the ability to produce, either     directly or through a <font color="blue">third party</font>, an <font color="blue">unlimited amount</font> of ARA The sale of     such self-produced ARA is limited annually, however, to the greater of     (i) 100 tons of ARA oil or (ii) any <font color="blue">amounts ordered by us</font> that DSM is unable     to fulfill</td>
    </tr>
    <tr>
      <td>During fiscal 2005, we <font color="blue">demonstrated</font> the ability to produce     limited amounts of ARA in our plants</td>
    </tr>
    <tr>
      <td>To <font color="blue">further improve</font> our overall ARA     supply chain, we have directly engaged a US-based provider of certain     post-<font color="blue">fermentation</font> ARA <font color="blue">manufacturing services</font> and have added <font color="blue">additional</font> ARA     downstream processing <font color="blue">capacity</font> at Kingstree</td>
    </tr>
    <tr>
      <td>Along with our pending ARA     extraction  <font color="blue"><font color="blue">capabilities</font> at</font> Kingstree, the addition of the third-party     <font color="blue">facility</font>  <font color="blue">provides us with multiple</font> US sites for the full downstream     processing of ARA     When combining our current DHA <font color="blue">production <font color="blue">capabilities</font></font> in <font color="blue">Winchester </font>and     <font color="blue">Kingstree </font>with DSM’s current ARA <font color="blue">production <font color="blue">capabilities</font></font> in Italy and the     US, we have production <font color="blue">capacity</font> for <font color="blue">DHA and ARA </font>products in excess of     dlra500 million in <font color="blue">annualized sales</font> to the <font color="blue">infant formula</font>, <font color="blue">dietary supplement</font>     and food and <font color="blue">beverage markets</font></td>
    </tr>
    <tr>
      <td>As such, our <font color="blue">production <font color="blue">capabilities</font></font> exceed     current demand; however, we have the ability to <font color="blue">manage production levels</font>     and, to a certain extent, control our <font color="blue">manufacturing costs</font></td>
    </tr>
    <tr>
      <td>Nonetheless, when     experiencing excess <font color="blue">capacity</font>, we may be unable to produce the required     quantities of oil cost-effectively</td>
    </tr>
    <tr>
      <td>We  also  have  several  other contractual <font color="blue"><font color="blue">agreement</font>s</font> with third-party     <font color="blue">manufacture</font>rs to assist in the production of our <font color="blue">nutritional oils</font></td>
    </tr>
    <tr>
      <td><font color="blue">Among     </font>them, we have an <font color="blue">agreement</font> for the production of DHA-S biomass that we sell     to <font color="blue">animal feed</font> companies or <font color="blue">process further</font> for use in the <font color="blue">adult supplement</font>     and  food  and  <font color="blue">beverage markets</font></td>
    </tr>
    <tr>
      <td>We currently have a <font color="blue">minimum purchase</font>     <font color="blue">commitment</font>  under  this <font color="blue">agreement</font> that <font color="blue">expires on</font> June 30, 2006</td>
    </tr>
    <tr>
      <td>As of     October 31, 2005, our <font color="blue">remaining obligation</font> was <font color="blue">approximately</font> dlra1dtta8 million</td>
    </tr>
    <tr>
      <td>We do not anticipate extending this third-party <font color="blue">arrangement</font> due to the     <font color="blue">recent refinement</font> and scale-up of our internal <font color="blue">production <font color="blue">capabilities</font></font> for     DHA-S  at  both our Winchester, Kentucky and Kingstree, South Carolina     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of our <font color="blue">nutritional oils</font> will depend, in part, on our     ability to <font color="blue">manufacture</font> these oils or have them <font color="blue">manufacture</font>d at large scale     on a <font color="blue">continuous basis</font> and at a <font color="blue">commercially</font> acceptable cost</td>
    </tr>
    <tr>
      <td>Our success     will also be <font color="blue">somewhat dependent on</font> our ability to align our <font color="blue">production with</font>     <font color="blue">customer demand</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">market demand subsides due</font> to our <font color="blue">inability</font> to meet     demand for our products, our results could be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>There can     also  be  no  assurance  that we will be able to <font color="blue">successfully optimize</font>     production of our <font color="blue">nutritional oils</font>, or continue to <font color="blue">comply with applicable</font>     <font color="blue">regulatory</font> <font color="blue">requirements</font>, including GMP <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Under the terms of     several of our <font color="blue">infant formula</font> licenses, our licensees may elect to                                         36       _________________________________________________________________           <font color="blue">manufacture</font> these oils <font color="blue">themselves</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently unaware</font> of any of our     licensees producing our oils or preparing to produce our oils, and estimate     that it would take a licensee a minimum of one year to implement a process     for making our oils</td>
    </tr>
    <tr>
      <td>ACQUISITIONS AND DISPOSITIONS       In September 2003, we purchased, through a wholly-owned subsidiary, certain     assets  and  assumed  certain <font color="blue">liabilities</font> of FermPro, which operated a     <font color="blue">fermentation</font> <font color="blue"><font color="blue">facility</font> located</font> in Kingstree, South Carolina</td>
    </tr>
    <tr>
      <td>The addition of     the FermPro <font color="blue">facility</font> added to our <font color="blue">production <font color="blue">capabilities</font></font> and has <font color="blue">allowed us</font>     to  establish  a  second manufacturing <font color="blue">facility</font> that now has redundant     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">purchase price</font> of the assets acquired and <font color="blue">liabilities</font>     assumed included a payment of <font color="blue">approximately</font> dlra12dtta2 million, comprised of     dlra5dtta4 million  in  cash,  124cmam788  shares of our <font color="blue">common stock valued at</font>     <font color="blue">approximately</font>   dlra5dtta6 million,   and   <font color="blue">approximately</font>   dlra1dtta2 million  in     <font color="blue">acquisition</font>-related fees and expenses</td>
    </tr>
    <tr>
      <td>In addition, a dlra10 million note was     assumed as part of the <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>The results of <font color="blue">operations</font> of <font color="blue">FermPro     </font>have been included in the <font color="blue">accompanying</font> consolidated statements of income     from the date of the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">purchase price</font> has <font color="blue">been allocated</font> to     the assumed assets and <font color="blue">liabilities</font> of FermPro <font color="blue">based on</font> their <font color="blue">relative fair</font>     values</td>
    </tr>
    <tr>
      <td>In April 2002, we completed our <font color="blue">acquisition</font> of <font color="blue">OmegaTech </font>for <font color="blue">approximately</font>     dlra54dtta1 million</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>dlra49dtta3 million of the <font color="blue">purchase price</font> was related     to the value of 1cmam765cmam728 shares of our common stock (dlra1dtta5 million of which     related  to  <font color="blue">OmegaTech </font> <font color="blue">transaction</font>  costs  paid by us), <font color="blue">approximately</font>     dlra2dtta1 million  was  for  our <font color="blue">acquisition</font>-related fees and expenses, and     <font color="blue">approximately</font> dlra2dtta7 million was related to the <font color="blue">fair value</font> of 154cmam589 vested     <font color="blue">OmegaTech </font><font color="blue">stock options</font> that were assumed as part of the <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>The     merger <font color="blue">agreement</font> also provides for <font color="blue">additional</font> stock <font color="blue">consideration</font> of up to     dlra40 million, subject to <font color="blue">certain pricing adjustments</font>, if <font color="blue">certain <font color="blue">milestones</font></font>     are met</td>
    </tr>
    <tr>
      <td>Two of these <font color="blue">milestones</font> relate to operating results (sales and     gross <font color="blue">profit margin</font> <font color="blue">objectives</font> by October 2003 and October 2004) and two     relate to <font color="blue"><font color="blue">regulatory</font> approvals</font> in the US and Europe</td>
    </tr>
    <tr>
      <td>One of the <font color="blue">regulatory</font>     approval <font color="blue">milestones</font> related to the granting of <font color="blue">Novel Foods </font>approval in     Europe for the <font color="blue">OmegaTech </font>DHA-S oil</td>
    </tr>
    <tr>
      <td>In June 2003, the <font color="blue">European Commission </font>    <font color="blue">granted approval</font> of the use of this oil in <font color="blue">certain foods</font> in the European     Community, meeting the <font color="blue">conditions</font> of this <font color="blue">regulatory</font> milestone</td>
    </tr>
    <tr>
      <td>Accordingly,     <font color="blue">approximately</font> 358cmam566 shares of Martek common stock, with a <font color="blue">fair market</font>     value of <font color="blue">approximately</font> dlra14dtta2 million, were <font color="blue">issued during</font> the <font color="blue">third quarter</font>     of fiscal 2003</td>
    </tr>
    <tr>
      <td>The payment of this <font color="blue">additional</font> <font color="blue">consideration</font> was <font color="blue">recorded as</font>     goodwill</td>
    </tr>
    <tr>
      <td><font color="blue">As of October </font>31, 2005, we do not believe the second <font color="blue">regulatory</font> milestone     has been achieved</td>
    </tr>
    <tr>
      <td>In addition, we do not believe that <font color="blue">either financial</font>     milestone related to sales and gross <font color="blue">profit margin</font> for the periods ended     October 31, 2004 and 2003 has been achieved</td>
    </tr>
    <tr>
      <td>The <font color="blue">representative</font> of the     former <font color="blue">OmegaTech </font><font color="blue">stockholders</font> has <font color="blue">advised us</font> that he believes that the     <font color="blue">common stock issuable with respect</font> to the second <font color="blue">regulatory</font> milestone as     well as the <font color="blue">financial milestone</font> related to the period ended October 31, 2003     should be issued</td>
    </tr>
    <tr>
      <td>Martek <font color="blue">disagrees with</font> that <font color="blue">conclusion</font></td>
    </tr>
  </tbody>
</table>